






Compound C




Compound D

FIG. 1 (CONT'D)




Compound 1a



Compound 2a

FIG. 1 (CONT'D)



Compound 3a

FIG. 1 (CONT'D)




FIG. 1 (CONT'D)






FIG. 1 (CONT'D)



EEV-PMO-MDX-2

2019

SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




FIG. 2 (CONT'D)




FIG. 3

Human Wi38 fibroblasts, 10% FBS, 1 h, LDH




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 11




FIG. 12

SUBSTITUTE SHEET (RULE 26)




FIG. 12 (CONT'D)




FIG. 13





FIG. 14A

FIG. 14B

FIG. 14C



For O-MOE^{GRR}-CPP and LNA^{GRR}-CPP12:




FIG. 16A

For PMO oligos:





FIG. 16B



LEGO




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21D




FIG. 22B




FIG. 22A




FIG. 22D




FIG. 22C




FIG. 22E




FIG. 22F




FIG. 23A




FIG. 23B




FIG. 24A

SUBSTITUTE SHEET (RULE 26)




FIG. 24B




FIG. 24C




FIG. 25




FIG. 26






FIG. 27

SUBSTITUTE SHEET (RULE 26)




Adenine morpholino monomer

FIG. 28A




Cytosine morpholino monomer

FIG. 28B



Guanine morpholino monomer

FIG. 28C



Thymine morpholino monomer

FIG. 28D





FIG. 29A



5'-conjugation, amide chemistry




FIG. 29C

3'-conjugation, amide chemistry




FIG. 29D

SUBSTITUTE SHEET (RULE 26)




FIG. 30




FIG. 31A




FIG. 31B




FIG. 32A




FIG. 32B




FIG. 32C




FIG. 32D




FIG. 33A




FIG. 33B




FIG. 33C




FIG. 33D




FIG. 34A




FIG. 34B




FIG. 34C




FIG. 35




FIG. 36

Compound (PMO-EEV)	Quantity (Before Desalting)	EEV Peptide Sequence	PMO Sequence
EEV-PMO-IRF5-1	12.7 mg	Ac-PKKRKV-Lys-cyclo(FNaIGrGrQ)-PEG12-OH	AGA ACG TAA TCA TCA GTG GGT TGG C
EEV-PMO-IRF5-2	12.4 mg	Ac-PKKRKV-Lys-cyclo(FGFGRRRQ)-PEG12-OH	AGA ACG TAA TCA TCA GTG GGT TGG C
EEV-PMO-IRF5-3	13.0 mg	Ac-PKKRKV-Lys-cyclo(FGFRRRRQ)-PEG12-OH	AGA ACG TAA TCA TCA GTG GGT TGG C
EEV-PMO-IRF5-4		Ac-PKKRKV-Lys-cyclo(FGFGRRRQ)-PEG12-OH	AGA ACG TAA TCA TCA GTG GGT TGG C

FIG. 37A




FIG. 37B




FIG. 37B (CONT'D)




FIG. 37B (CONT'D)




FIG. 37C




FIG. 37C (CONT'D)




FIG. 37C (CONT'D)




FIG. 37D

SUBSTITUTE SHEET (RULE 26)




FIG. 37D (CONT'D)




FIG. 37D (CONT'D)




FIG. 37E




FIG. 37E (CONT'D)




FIG. 37E (CONT'D)




FIG. 38





FIG. 39

FIG. 40



PCT/US22/71489 22 June 2022 (22.06.2022)





FIG. 41

PCT/US22/71489 22 June 2022 (22.06.2022)

72/101



SUBSTITUTE SHEET (RULE 26)

FIG. 42

73/101
PCT/US22/71489 22 June 2022 (22.06.2022)





FIG. 43

PCT/US22/71489 22 June 2022 (22.06.2022)



Triceps
FIG. 44

PCT/US22/71489 22 June 2022 (22.06.2022)

75/101




FIG. 45

76/101



4




FIG. 47




FIG. 48




FIG. 49




FIG. 50




FIG. 51




FIG. 52

FIG. 53B





FIG. 53A






FIG. 53C

FIG. 54B





FIG. 54A






FIG. 54C

FIG. 55B





FIG. 55A






FIG. 55C

FIG. 56B




FIG. 56A





FIG. 56C






FIG. 57




FIG. 58

FIG. 59A




FIG. 59B




FIG. 59C




FIG. 59D




FIG. 60B




FIG. 60A




FIG. 60D




FIG. 60C




FIG. 61





FIG. 62






FIG. 63

FIG. 64




FIG. 65

